Search results
Merck stops testing combo drug for skin cancer as more patients discontinue
Reuters via Yahoo News· 2 days agoThis is the latest setback for the experimental drug, vibostolimab, and the related promising new...
Merck halts phase 3 TIGIT trial after immune-mediated adverse events prompt discontinuations
FierceBiotech· 2 days agoMerck & Co. has bailed early on a phase 3 test of the anti-TIGIT antibody vibostolimab after a high...
Merck Expands Access to High-Quality Maternal Care for More
3BL CSRwire· 2 days agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Merck for Mothers, the company’s global maternal health initiative ...
Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side...
Quartz· 2 days agoMerck announced Monday that it is pulling the plug on its phase 3 trial of an experimental...
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Zacks· 6 days agoFree Report) is one of the stocks most watched by Zacks.com visitors lately. Shares of this pharmaceutical company have returned +2.2% over the past month versus the Zacks S&P 500 composite's ...
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma...
Benzinga· 2 days agoMonday, Merck & Co Inc MRK announced the discontinuation of the vibostolimab and pembrolizumab...
Bars, music venues left in limbo after South Carolina lawmakers fail to address liquor liability
WYFF 4 Greenville· 18 hours agoBar and music owners will now have to wait until next year to hopefully get help from lawmakers in...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 3 minutes agoThe MASH space has heated up with the FDA approval of the first-ever treatment, a drug called...
Data-Based Insights About Merck & Co Inc
Stocks Register· 6 days agoMerck & Co Inc (NYSE:MRK) price on Thursday, May 09, rose 0.08% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $129.66. A look ...
Merck treatment for a type of uterus cancer fails trial
WHTC 1450 Holland· 6 days ago(Reuters) - Merck said on Thursday its treatment for a type of uterus cancer did not meet the main...